Results 1 to 10 of about 13,874 (194)

Valganciclovir Inhibits Human Adenovirus Replication and Pathology in Permissive Immunosuppressed Female and Male Syrian Hamsters [PDF]

open access: yesViruses, 2015
Adenovirus infections of immunocompromised pediatric hematopoietic stem cell transplant patients can develop into serious and often deadly multi-organ disease. There are no drugs approved for adenovirus infections.
Karoly Toth   +7 more
doaj   +4 more sources

Valganciclovir Dosing Strategies for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients: A Comparative Single-Center Study [PDF]

open access: yesViruses
Optimal valganciclovir dosing for cytomegalovirus (CMV) prophylaxis in pediatric solid organ transplant recipients remains difficult due to variable pharmacokinetics.
Samar Alharbi   +9 more
doaj   +2 more sources

Cost-utility and budget impact analyses of valganciclovir for cytomegalovirus retinitis in patients with human immunodeficiency virus in Thailand [PDF]

open access: yesJournal of Pharmaceutical Policy and Practice
Background Cytomegalovirus retinitis (CMVR) is an opportunistic infection frequently seen in people living with HIV (PLHIV) and can cause blindness. Intravenous (IV) ganciclovir is a typical CMVR treatment in Thailand, but oral valganciclovir is a more ...
Tippawan Wongwian   +2 more
doaj   +2 more sources

Evaluation of neutropenia secondary to mycophenolate mofetil associated with valganciclovir in liver transplant patients [PDF]

open access: yesFarmacia Hospitalaria, 2021
Objective: Immunosuppressive drugs are necessary to avoid or reduce the risk of rejection of transplanted organs. The immunosuppression generated may result in these patients needing antibiotics and antivirals to be prescribed to them in conjunction ...
Alejandro Ferrer-Machín   +5 more
doaj   +1 more source

Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation

open access: yesTherapeutic Advances in Hematology, 2021
Background: Letermovir prophylaxis is currently the standard of care for the prevention of cytomegalovirus (CMV) infections in allogeneic hematopoietic stem-cell transplantation (allo-HSCT).
Po-Hsien Li   +5 more
doaj   +1 more source

Development and Validation of Valganciclovir and its Active Metabolite Ganciclovir Determination in Human Plasma by HPLC-MS/MS Method

open access: yesРазработка и регистрация лекарственных средств, 2021
Introduction. Currently, physicochemical methods of quantification are actively used to determine the content of drugs in biological fluids. High-performance liquid chromatography with various detection methods is particularly widespread. One of the most
T. N. Komarov   +7 more
doaj   +1 more source

Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. [PDF]

open access: yesPLoS ONE, 2009
BACKGROUND:Several anti-viral drugs have demonstrated efficacy in preventing Cytomegalovirus (CMV) infections in solid organ transplant (SOT) patients.
Andre C Kalil   +3 more
doaj   +1 more source

Oral valganciclovir in human immunodeficiency virus-positive patients suffering from cytomegalovirus retinitis at a tertiary care hospital in North India

open access: yesIndian Journal of Ophthalmology, 2022
Purpose: To study clinical efficacy of valganciclovir in cytomegalovirus retinitis (CMVR) in human immunodeficiency virus (HIV)-positive-positive patients in a tertiary care clinic in a developing nation.
Ashish Markan   +4 more
doaj   +1 more source

Development and Validation of Valganciclovir and its Active Metabolite Ganciclovir Determination in Human Plasma by HPLC-UV Method

open access: yesРазработка и регистрация лекарственных средств, 2020
Introduction. Viral infections are a serious problem that occurs during the use of immunosuppressants in preparation for organ transplantation and in the postoperative period.
T. N. Komarov   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy